← boardnext 2026-08
VANI
Vivani Medical, Incdistress 7/10 · high distress / dilution risk$1.37-1%today-27% from 52w high
Metabolic / Obesity 2
Lead: chronic weight management · target GLP-1 · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$20M
Runway
0.8 yrs
Shares 1y
+46%
Price & events
-6.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+1.5%
1W
+15.1%
1M
+4.6%
3M
-7.4%
6M
-12.7%
1Y
+7.0%
2Y
-88.9%
5Y
-80.6%
All
Overview
- Market Cap
- $118.16M
- Volume
- 29.95K
- 52 Week Range
- $0.94 – $1.87
- Total Shares
- 86.24M
- Float Shares
- 34.89M
- Short %
- 1.00%
- % Held by Insiders
- 57.94%
- % Held by Institutions
- 6.48%
- RVOL
- 0.04x
- Beta
- 3.29
Pipeline stages · 2 programs
Semaglutide (Wegovy) weekly injectionGLP-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mLGLP-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-08-31 final ~2027-03-31 | Phase 1 | Semaglutide (Wegovy) weekly injection | Obesity & Overweight | 20 | not yet recruiting |
| 2025-08-21 | Phase 1 | Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL | Overweight and Obesity, Type2diabetes | 24 | completed |
Catalyst news & presentations · 12
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)NPM-139 · IND application to support Phase 2 dose-ranging studySEC 8-K
- mid-2026Guided 55%trial initiationsecondaryPhase 1NPM-139 · SLIM-1 Phase 1 clinical trial of semaglutide implant in obesity and chronic weight managementSEC 8-K
- by the end of 2026Guided 40%readoutPhase 1NPM-139 · Top-line SLIM-1 resultsSEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- August 2026trial initiationsecondarySLIM-1 · first dosing expectedSEC 8-K
- mid-year 2026trial initiationsecondaryPhase 1NPM-139 · Initiation of SLIM-1 Phase 1 study of low-dose NPM-139SEC 8-K
- June 4, 2026 at 11:05 a.m. Easternconferencedata presentationsecondaryVivani to present at Jefferies Global Healthcare Conference in New York.SEC 8-K
- 2025readoutPhase 1exenatide implant · Data from LIBERATE-1 trial projected to be available.SEC 8-K
- 2025readoutPhase 1NPM-115 · Data from first-in-human study LIBERATE-1 expectedSEC 8-K
- mid-2025readoutPhase 1NPM-115 · Top-line results from LIBERATE-1 study of NPM-115 (exenatide implant) in obese or overweight individuals.SEC 8-K
- fourth quarter of 2024trial initiationsecondaryPhase 1exenatide implant · First-in-human trial LIBERATE-1 with GLP-1 (exenatide) implant for chronic weight management.SEC 8-K
- fourth quarter of 2024trial initiationsecondaryPhase 1NPM-115 · Initiate first-in-human study LIBERATE-1 for NPM-115SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $4 (+180% upside) · 3 analysts
- 2026-06-23Lake StreetBuy
- 2026-03-31HC Wainwright & Co.Buy
- 2025-09-02HC Wainwright & Co.Buy
- 2025-05-19HC Wainwright & Co.Buy
- 2025-04-16HC Wainwright & Co.Buy
- 2025-04-04HC Wainwright & Co.Buy
Competitors — GLP-1
Recent news
- 2026-07-20Enterprise value to revenue forward of Vivani Medical Inc. – FWB:U5P - TradingView
- 2026-07-17ClearOne (CLRO) to acquire Cortigent, cede control to Vivani in stock deal - Stock Titan
- 2026-07-16Form 4 Vivani Medical Inc For: 16 July By Investing.com - Investing.com Nigeria
- 2026-07-16Vivani Medical (NASDAQ: VANI) Targets August Human Trial For Semaglutide Implant Following Novo Nordisk Evaluation Deal - foreignpolicyjournal.com
- 2026-07-16Vivani Medical director Gregg Williams buys $1m in stock By Investing.com - Investing.com Nigeria
- 2026-07-16Vivani Medical director Gregg Williams buys $1m in stock - Investing.com
- 2026-07-16Vivani Medical says first SLIM-1 dosing expected in August 2026 after CEO presentation - TradingView
- 2026-07-16Vivani Medical director, 10% owner Gregg Williams reports purchase of USD 999,999 common shares - Bitget
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.